Zevra Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Zevra Therapeutics

07/03/2025 20:37

Zevra Therapeutics Inc ZVRA.OQ ZVRA.O is expected to show a fall in quarterly revenue when it reports  results on March 11 for the period ending December 31 2024

The Celebration Florida-based  company is expected to report a 32.5% decrease in revenue to $8.926 million from $13.22 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Zevra Therapeutics Inc is for a loss of 40 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Zevra Therapeutics Inc is $21.00​, above​ its last closing price of $8.05. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.42
-0.42
-0.69
Missed
-63.8
Jun. 30 2024
-0.44
-0.43
-0.48
Missed
-10.6
Mar. 31 2024
-0.48
-0.48
-0.40
Beat
16.3​
Dec. 31 2023
-0.19
-0.27
-0.40
Missed
-49.1
​​Sep. 30 2023
-0.30
-0.30
-0.40
Missed
-34.5
Jun. 30 2023
-0.37
-0.34
-0.15
Beat
56.3​
Mar. 31 2023
-0.24
-0.23
-0.34
Missed
-46.2
Dec. 31 2022
-0.17
-0.17
-0.26
Missed
-50

This summary was machine generated March 7 at 20:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)